Interim analysis of the HER2-overexpressing cohort (overexpressing HER2 centrally confirmed, IHC 2+ or 3+) has shown preliminary evidence of antitumor activity in 49 heavily pre-treated patients with HER2-overexpressing NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.